Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Abstract Background and Aim In this retrospective study, we evaluated the effects of pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hypertriglyceridemia using non‐invasive stiffness‐based models, including magnetic resonance elastography (...

Full description

Bibliographic Details
Main Authors: Takeshi Ichikawa, Haruki Oba, Mai Owada, Kazuki Watanabe, Tsubasa Yoshimura, Ayako Fuchigami, Atsushi Nakamura
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:JGH Open
Subjects:
hyperglyceridemia
magnetic resonance elastography combined with fibrosis‐4 index
magnetic resonance imaging‐aspartate aminotransferase score
metabolic dysfunction‐associated steatotic liver disease
pemafibrate
Online Access:https://doi.org/10.1002/jgh3.13012

Internet

https://doi.org/10.1002/jgh3.13012

Similar Items